InsidersTradesSigma
Enovis CORP Stock: price and management transactions · United States · SEC (Form 4)
Follow the Enovis CORP share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Enovis CORP has logged 5 public disclosures. Market capitalisation: €1.3bn. The latest transaction was filed on 16 June 2026 (Acquisition). Among the most active insiders: Engert Oliver. Every trade is accessible without an account.
5
Insider Decl.
0
Thresholds
·
4 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Enovis CORP Strong Buy (bullish), based on 10 analysts. Average price target: US$42.30.
49Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 21,784 of 25,750 companies
27.0
score / 100
Value25
Quality29
FCF yld1.4%
Earn yld-81%
EV/EBITDA·
ROE-55%
Gross mgn60%
Net mgn-53%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 June 2026
Declarations5 total
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-273151:0
Ideal exit: 12 Mar 2027 (T+270)
200 sharesCommon stock, par value $0.001SEC:0001193125-26-271546:0
Ideal exit: 8 Mar 2027 (T+270)
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-271546:1
Ideal exit: 8 Mar 2027 (T+270)
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-268213:0
Ideal exit: 7 Mar 2027 (T+270)
12,634 shares@ US$25.990.020% mcap100.0% of flowCommon stock, par value $0.001SEC:0001193125-26-224739
5 of 5 declarations
About Enovis CORP
Enovis Corporation (NYSE: ENOV) is a United States–based medical technology company focused on orthopedics and rehabilitation. For French-speaking investors, it fits the profile of a specialized health-tech industrial group with a defensive end market and a business model built around clinically differentiated solutions that aim to improve patient outcomes and streamline provider workflows. The company traces its modern corporate history to Colfax, founded in 1995, and later reoriented toward medical technology before adopting the Enovis name. Its operating headquarters are in Dallas, Texas, and its commercial footprint is international. ([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai)) Enovis’ portfolio is organized around two main solution sets. First, reconstructive orthopedics, including products and technologies for hip, knee, foot and ankle care, as well as implant-related systems and adjacent surgical solutions. Second, recovery sciences and prevention, which includes rigid bracing, orthopedic soft goods, vascular compression systems, hot and cold therapy products, and rehabilitation-science offerings such as bone growth stimulators and electrical stimulators used in pain management. This mix gives the company exposure across the continuum of care, from injury prevention to post-operative recovery. ([fintel.io](https://fintel.io/doc/sec-enovis-corporation-1420800-10k-2026-february-26-20510-8732?utm_source=openai)) From a competitive standpoint, Enovis operates in a crowded global market dominated by larger medtech players, but its strategy is built on specialization, innovation, and category-focused brands. Its value proposition is less about scale leadership and more about targeted clinical utility, product differentiation, and workflows that resonate with surgeons, hospitals, care networks, and patients. The company’s foot-and-ankle, bracing, and recovery franchises help it maintain relevance in high-need orthopedic niches. ([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai)) Geographically, Enovis has a broad international presence, with operations and sales in North America, Europe, and other global markets. Recent corporate developments underscore an active portfolio-management approach: the LimaCorporate acquisition, completed in early 2024, strengthened its reconstructive platform; in October 2025 the company divested the Dr Comfort Footcare Solutions product line; and in July 2025 it launched the Manafuse Bone Growth Stimulator. Enovis also showcased new foot-and-ankle technologies at AOFAS 2025, including the Pecaplasty system and other branded solutions, which signals continued investment in innovation and commercial execution. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/e/NYSE_ENOV_2023.pdf?utm_source=openai)) In short, Enovis is a NYSE-listed U.S. medtech company whose core thesis rests on orthopedic specialization, rehabilitation products, and a pipeline of clinically differentiated offerings supported by acquisitions, divestitures, and product launches. ([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai))
